文献速递湿疹皮炎与荨麻疹

阿布昔替尼诱导、随机撤药与再治疗在中重度特应性皮炎中的III期JADE REGIMEN研究

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
PubMed 文献 · J Am Acad Dermatol · 2021-08-17

JADE REGIMEN III期试验纳入1233例中重度特应性皮炎患者,经开放标签阿布昔替尼200mg诱导12周后,798例应答者(64.7%)随机分为阿布昔替尼200mg、100mg或安慰剂维持40周。维持期 flare 概率分别为18.9%、42.6%和80.9%;出现 flare 后接受阿布昔替尼200mg联合局部治疗抢救,各组多数可重新获得应答。

要点

  • 阿布昔替尼200mg诱导12周应答率为64.7%。
  • 维持期200mg组 flare 概率最低(18.9%)。
  • 抢救治疗可有效重新捕获应答。

核心结论

  • 阿布昔替尼诱导治疗有效,多数继续治疗应答者未出现 flare,抢救治疗可有效重新获得应答。

研究设计与样本

  • III期随机撤药试验,1233例中重度特应性皮炎患者接受开放标签阿布昔替尼200mg诱导12周,798例应答者按1:1:1随机分配至盲法阿布昔替尼200mg、100mg或安慰剂维持40周。

主要发现

  • 维持期 flare 概率在阿布昔替尼200mg组为18.9%、100mg组为42.6%、安慰剂组为80.9%。
  • 出现 flare 后接受抢救治疗(阿布昔替尼200mg联合局部治疗),200mg组、100mg组和安慰剂组分别有36.6%、58.8%和81.6%重新获得IGA 0/1应答。
  • 抢救治疗后分别有55.0%、74.5%和91.8%重新获得EASI应答。
  • 维持期阿布昔替尼200mg和100mg组分别有63.2%和54.0%的患者发生不良事件。

临床怎么用

  • 对阿布昔替尼200mg诱导12周应答的中重度特应性皮炎患者,可继续200mg维持以降低 flare 风险。
  • 出现 flare 时可采用阿布昔替尼200mg联合局部治疗进行抢救,以重新获得应答。

局限性

  • 方案定义的 flare 尚未确立,限制了研究结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. OBJECTIVE: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, and response to treatment reintroduction following flare (JAK1 Atopic Dermatitis Efficacy and Safety [JADE] REGIMEN: National Clinical Trial 03627767). METHODS: Patients with moderate-to-severe atopic dermatitis responding to open-label abrocitinib 200 mg monotherapy for 12 weeks were randomly assigned in a 1:1:1 ratio to blinded abrocitinib (200 or 100 mg) or placebo for 40 weeks. Patients experiencing flare received rescue treatment (abrocitinib 200 mg plus topical therapy). RESULTS: Of 1233 patients, 798 responders to induction (64.7%) were randomly assigned. The flare probability during maintenance was 18.9%, 42.6%, and 80.9% with abrocitinib 200 mg, abrocitinib 100 mg, and placebo, respectively. Among patients with flare in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups, 36.6%, 58.8%, and 81.6% regained investigator global assessment 0/1 response, respectively, and 55.0%, 74.5%, and 91.8% regained eczema area and severity index response, respectively, with rescue treatment. During maintenance, 63.2% and 54.0% of patients receiving abrocitinib 200 and 100 mg, respectively, experienced adverse events. LIMITATIONS: The definition of protocol-defined flare was not established, limiting the generalizability of findings. CONCLUSION: Induction treatment with abrocitinib was effective; most responders continuing abrocitinib did not flare. Rescue treatment with abrocitinib plus topical therapy effectively recaptured response.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2021. PMID: 34416294. doi:10.1016/j.jaad.2021.05.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。